A phase I single ascending dose (SAD) trial of SAGE 718 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 27 Apr 2017
At a glance
- Drugs SAGE 718 (Primary)
- Indications Smith-Lemli-Opitz syndrome
- Focus Adverse reactions; First in man
- 27 Apr 2017 Status changed from planning to recruiting according to a SAGE Therapeutics media release.
- 16 Nov 2016 New trial record
- 03 Nov 2016 According to a Sage Therapeutics media release, data readout from this trial is epxected in the second half of 2017.